Journal
GENES TO CELLS
Volume 21, Issue 10, Pages 1049-1058Publisher
WILEY-BLACKWELL
DOI: 10.1111/gtc.12405
Keywords
-
Categories
Funding
- JSPS KAKENHI [15K06978, 25860020]
- Takeda Science Foundation
- Grants-in-Aid for Scientific Research [15K06978, 25860020] Funding Source: KAKEN
Ask authors/readers for more resources
Over-expression and aberrant activation of tyrosine kinases occur frequently in human cancers. Various tyrosine kinase inhibitors (TKIs) are under clinical use, but acquisition of resistance to these drugs is a major problem. Here, we studied the interaction between two drug-resistant mutants of fibroblast growth factor receptor 1 (FGFR1), N546K and V561M, and four ATP-competitive inhibitors, ponatinib, dovitinib, PD173074 and BGJ-398. Among these protein-drug systems, the only marked reduction in affinity was that of PD173074 for the V561M mutant. We also examined the interaction of these FGFR1 variants to AMP-PNP, a nonhydrolyzable analogue of ATP, and showed that N546K showed increased affinity for the ATP analogue as compared with the wild type. These findings will help to clarify the mechanism of drug resistance in mutant tyrosine kinases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available